Sustained Remission after Rituximab-containing Chemotherapy for Intravascular Large B-cell Lymphoma

• Shimada Kazuyuki

  Department of Hematology, Ogaki Municipal Hospital Department of Hematology and Oncology, Nagoya University Graduate School of Medicine

• Kosugi Hiroshi

  Department of Hematology, Ogaki Municipal Hospital

• Narimatsu Hiroto

  Department of Hematology and Oncology, Nagoya University Graduate School of Medicine

• Shimada Satoko

  Department of Pathology of Biological Response, Nagoya University Graduate School of Medicine

• Suzuki Tatsuya

  Department of Hematology, Ogaki Municipal Hospital Department of Hematology and Oncology, Nagoya University Graduate School of Medicine

• Ito Masafumi

  Department of Pathology, Japanese Red Cross, Nagoya First Hospital

• Kinoshita Tomohiro

  Department of Hematology and Oncology, Nagoya University Graduate School of Medicine

• Mori Naoyoshi

  Department of Pathology of Biological Response, Nagoya University Graduate School of Medicine

• Naoe Tomoki

  Department of Hematology and Oncology, Nagoya University Graduate School of Medicine

抄録

Intravascular large B-cell lymphoma (IVL) is rare aggressive disseminated lymphoma associated with poor outcomes. Rituximab is a novel molecular agent that can reportedly improve outcomes for patients with diffuse large B-cell lymphoma. However, the safety and efficacy of rituximab in patients with IVL are unclear. A 76-year-old woman was hospitalized due to altered consciousness, fever and respiratory abnormalities. Definitive diagnosis of IVL was obtained following repeated biopsies of bone marrow. The patient received chemotherapy consisting of cyclophosphamide, vincristine, doxorubicin, prednisolone, and rituximab (R-CHOP), and achieved complete remission after 3 courses of treatment. She has remained in complete remission for over 3 years after diagnosis. This report suggests that rituximab-containing regimens could be safe and effective for elderly patients with IVL. [J Clin Exp Hematopathol 48(1) : 25-28, 2008]

収録刊行物

• Ｊｏｕｒｎａｌ　ｏｆ　Ｃｌｉｎｉｃａｌ　ａｎｄ　Ｅｘｐｅｒｉｍｅｎｔａｌ　Ｈｅｍａｔｏｐａｔｈｏｌｏｇｙ

  Ｊｏｕｒｎａｌ　ｏｆ　Ｃｌｉｎｉｃａｌ　ａｎｄ　Ｅｘｐｅｒｉｍｅｎｔａｌ　Ｈｅｍａｔｏｐａｔｈｏｌｏｇｙ 48 (1), 25-28, 2008

  日本リンパ網内系学会

キーワード

• intravascular large B-cell lymphoma
• rituximab
• combination chemotherapy

詳細情報

• CRID: 1390001204702611200
• NII論文ID: 10021246736
• NII書誌ID: AA11556796
• DOI: 10.3960/jslrt.48.25
• ISSN: 18809952
• ISSN: 13464280
• Web Site: https://search.jamas.or.jp/link/ui/2008264834
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可